糖尿病性肝病诊治进展

doi:10.3969/j.issn.1672-5069.2018.04.050

Abstract

Abstract: Diabetic hepatopathy (DH) is a complications of diabetes, most commonly arised from non-alcoholic fatty liver disease and glycogenic hepatopathy. DH has a high morbidity and always leads to serious clinical consequences. However, the disease has been neglected to date. In this review, we summarized the findings regarding the clinical and pathological features, mechanisms and therapeutic strategies of the disease.

Key words: Diabetic hepatopathy, Non-alcoholic fatty liver disease, Glycogenic hepatopathy

Yang Yan, Wang Xuan. Diagnosis and treatment of patients with diabetic hepatopathy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 653-656.

References

[1] Xu Y,Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults. JAMA,2013,310(9):948-959.
[2] Tolman KG,Fonseca V,Dalpiaz A,et al.Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care,2007,30(3):734-743.
[3] Porepa L,Ray JG,Sanchez-Romeu P,et al.Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ,2010,182(11):E526-531.
[4] de Marco R,Locatelli F,Zoppini G,et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care,1999,22(5):756-761.
[5] Angulo P.Nonalcoholic fatty liver disease. N Engl J Med,2002,346(16):1221-1231.
[6] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订). 中华内科杂志,2010,49(3):275-278.
[7] Masarone M,Rosato V,Aglitti A,et al.Liver biopsy in type 2 diabetes mellitus:Steatohepatitis represents the sole feature of liver damage. PLoS One,2017,12(6):e0178473.
[8] European Association for the Study of the L,European Association for the Study of D European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts,2016,9(2):65-90.
[9] Reeder SB,Cruite I,Hamilton G,et al.Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging,2011,34(4):729-749.
[10] 韦敏怡,冼苏,秦映芬,等. 糖尿病患者肝脏病变的病理研究. 中国糖尿病杂志,2005,13(6):454-455.
[11] Wan Y,Garner J,Wu N,et al.Role of stem cells during diabetic liver injury. J Cell Mol Med,2016,20(2):195-203.
[12] Takamatsu S,Noguchi N,Kudoh A,et al.Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology,2008,55(82-83):609-614.
[13] Raza H,Prabu SK, John A,et al.Impaired mitochondrial respiratory functions and oxidative stress in streptozotocin-induced diabetic rats. Int J Mol Sci,2011,12(5):3133-3147.
[14] Unal D,Aksak S,Halici Z,et al.Effects of diabetes mellitus on the rat liver during the postmenopausal period. J Mol Histol,2011,42(3):273-287.
[15] Grigorov I,Bogojevic D,Jovanovic S,et al.Hepatoprotective effects of melatonin against pronecrotic cellular events in streptozotocin-induced diabetic rats. J Physiol Biochem,2014,70(2):441-450.
[16] Ortiz-Avila O,Gallegos-Corona MA,Sanchez-Briones LA,et al.Protective effects of dietary avocado oil on impaired electron transport chain function and exacerbated oxidative stress in liver mitochondria from diabetic rats. J Bioenerg Biomembr,2015,47(4):337-353.
[17] Canbay A,Friedman S,Gores GJ.Apoptosis:the nexus of liver injury and fibrosis. Hepatology,2004, 39(2):273-278.
[18] Zhang Q,Li Y,Liang T,et al.ER stress and autophagy dysfunction contribute to fatty liver in diabetic mice. Int J Biol Sci,2015,11(5):559-568.
[19] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L,et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology,2015,149(2):367-378, e365; quiz e314-365.
[20] Esposito K,Marfella R,Ciotola M,et al.Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA,2004,292(12):1440-1446.
[21] Misciagna G,Del Pilar Diaz M,Caramia DV,et al. Effect of a low glycemic index mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging,2017,21(4):404-412.
[22] Donadon V,Balbi M,Mas MD,et al.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int,2010,30(5):750-758.
[23] 信丰智,范建高. 欧洲非酒精性脂肪性肝病诊疗指南简介. 实用肝脏病杂志,2016,4(19):519-520.
[24] Mazzotti A,Caletti MT,Marchignoli F,et al.Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease Dig Liver Dis,2017,49(3):235-240.
[25] Gentile S,Turco S,Guarino G,et al.Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab,2001,3(1):33-40.
[26] Gentile S,Guarino G,Romano M,et al.A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol,2005,3(2):184-191.
[27] Armstrong MJ,Gaunt P,Aithal GP,et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN):a multicentre,double-blind,randomised,placebo-controlled phase 2 study. Lancet,2016,387(10019):679-690.
[28] Torbenson M,Chen YY,Brunt E,et al.Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol,2006,30(4):508-513.
[29] Ikarashi Y,Kogiso T,Hashimoto E,et al.Four cases of type 1 diabetes mellitus showing sharp serum transaminase increases and hepatomegaly due to glycogenic hepatopathy. Hepatol Res,2017,47(3):E201-E209.
[30] Mukewar S,Sharma A,Lackore KA,et al.Clinical,biochemical,and histopathology features of patients with glycogenic hepatopathy. Clin Gastroenterol Hepatol,2017,15(6):927-933.
[31] Von Sengbusch A,Tannapfel A,Klein HH,et al.Hepatomegaly and elevated transaminases in a 24-year-old with type I diabetes mellitus. Internist (Berl),2010,51(1):84-87.
[32] Saadi T.Glycogenic hepatopathy:a rare disease that can appear and resolve rapidly in parallel with glycemic control. Isr Med Assoc J,2012,14(4):269-270.
[33] Van den Brand M,Elving LD,Drenth JP,et al. Glycogenic hepatopathy:a rare cause of elevated serum transaminases in diabetes mellitus. Neth J Med,2009,67(11):394-396.
[34] Ferrer JC,Favre C,Gomis RR,et al.Control of glycogen deposition. FEBS Lett,2003,546(1):127-132.
[35] Parmar N,Atiq M,Austin L,et al.Glycogenic hepatopathy: thinking outside the box. Case Rep Gastroenterol,2015,9(2):221-226.

Diagnosis and treatment of patients with diabetic hepatopathy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[2]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[3]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[4]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[5]	Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.
[6]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.
[7]	Song Na, Liu Xiaoyan, Liu Chang, et al.. Changes of plasma thyrotropin levels in patients with nonalcoholic fatty liver disease and type 2 diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 65-68.
[8]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[9]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[10]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[11]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[12]	Xie Zhanfeng, Jia Jizhen, Zhao Shufang. Combination of notoginseng total saponin and silybin in treatment of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 623-624.
[13]	Zhao Wentao, Cao Gaofeng, Jiao Xiaohong, et al. Efficacy of puerarin combined with metformin in the treatment of patients with non-alcoholic fatty liver disease and prediabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 409-412.
[14]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.
[15]	Xin Fengzhi, Cao Haixia, Fan Jiangao. Glucagon-like peptide-1 in melioration of non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 313-316.